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Introduction
Multiparametric magnetic resonance imaging (mpMRI) 
of the prostate is an established imaging technique for the 
detection of prostate cancer (1). It utilizes T2-weighted 
imaging, diffusion-weighted imaging (DWI) and dynamic 
contrast-enhanced (DCE) imaging to stratify the probability 
of prostate cancer, in accordance to PI-RADS (2). 
mpMRI has been shown to improve the detection of 
clinically significant cancer while reducing the detection 
of insignificant cancers compared to standard systematic 
transrectal ultrasound-guided biopsy (3,4). By identifying 
the most suspicious areas within the prostate, targeted 
biopsy can be performed, thus potentially reducing the 
number of biopsy cores and accompanying morbidity (5,6).
However, studies have shown significant overlap of DWI 
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and DCE imaging findings between malignancy and benign 
conditions such as prostatitis and stromal hyperplasia (7,8). 
Development of newer quantitative imaging techniques such 
as intravoxel incoherent motion (IVIM), diffusion tensor 
imaging (DTI) and diffusion kurtosis imaging (DKI), allow 
quantitative assessment and show potential in improving 
cancer detection and predicting tumor aggressiveness (9-11).
T2-mapping using MRI is a quantitative technique where 
basically the T2-relaxation times of tissues can be derived 
from a series of T2-weighted spin-echo sequences or from 
the echoes of a spin-echo multi-echo sequence and then be 
encoded, for example, into a color map (12). This technique 
provides functional information in terms of the different 
sizes of the water compartments as well as the different 
proportions of stromal and glandular tissue between normal 
and malignant prostatic tissue, to complement anatomical 
and spatial information provided by standard T2-weighted 
imaging (13). T2-mapping is well-established for evaluation 
of brain and cardiac tissue as well as changes in hyaline 
cartilage (14-16). Preliminary studies have also shown 
that T2-mapping can be useful in differentiating prostate 
malignancy from benign prostatic tissue based on differences 
in T2-relaxation times (17,18). One study in particular 
proposed a threshold T2-relaxation time of 99 ms to achieve 
a 92% sensitivity (Sn) and 97% specificity (Sp) for cancer 
detection in the peripheral zone (PZ) (19). However, the 
addition of a mapping sequence increases the overall prostate 
MR protocol acquisition time. This might be compensated 
by a mapping sequence that allows the reconstruction of a 
simulated T2-weighted image that could be used instead of 
the standard T2-weighted image.
We aim to evaluate the clinical utility of combined T2-




This prospective single-center study was approved by the 
institutional board of Charité University Hospital—Campus 
Benjamin Franklin (No. EA4/010/16) and informed consent 
was taken from all the patients.
Subjects were recruited between December 2016 and 
May 2018. Prostate MRI was clinically indicated in all 
subjects and requested by a referring doctor. Inclusion 
criteria were: (I) clinical suspicion for prostate cancer based 
on either a raised serum prostate-specific antigen (PSA) 
defined as above 4 ng/mL at our institution, a palpable 
nodule on digital rectal examination, a suspicious finding 
on trans-rectal ultrasound or a combination thereof and 
(II) no histologically-proven prostate cancer (Gleason 
score ≥6) at time of MRI. Exclusion criteria were: (I) 
contraindications to intravenous gadolinium-based 
contrast, for example moderate renal impairment (eGFR 
<60 mL/min/1.73 m2) or allergy, (II) MRI-incompatible 
implants, (III) prior prostate biopsy, (IV) treatment for 
prostate cancer or systemic therapy for benign prostatic 
hypertrophy (BPH), (V) the inability to complete the 
full MRI study, for example due to claustrophobia or 
physical handicap, (VI) imaging artefacts that significantly 
degraded image quality. All included subjects provided 
written informed consent prior to the MRI scan. Patients 
who met all inclusion and exclusion criteria were screened 
consecutively. Forty-one patients were enrolled and gave 
written informed consent for this study. One patient could 
not complete the MRI scan due to claustrophobia. No 
patients were excluded due to poor MRI image quality. 
Forty patients completed the MRI scans and were included 
as final cohort in this study. A total of 80 prostatic zones 
[40 PZ, 40 transition zone (TZ)] were analyzed. Mean 
patient age was 70.3 (range, 57 to 84) years. Biopsy 
results were available in 14 out of 40 patients, either from 
systematic or targeted biopsies, performed after the MRI 
scan. Prostate malignancy was subsequently confirmed 
by biopsy in 11 patients (Gleason 6=1 patient, Gleason 
7=6 patients, Gleason 8=4 patients). Three patients had 
negative biopsy results.
Imaging technique
All scans were performed on a 3 Tesla MR scanner 
(Magnetom Skyra, Siemens Healthineers, Erlangen, 
Germany) using body phased-array receiver coil (18-channel, 
3 rows of 6 elements each) with an integrated spine-array 
receiver coil (32-channel, 8 rows of 4 elements each).
T2-mapping of the whole prostate was performed 
using a vendor provided works-in-progress model-based 
accelerated T2-mapping multi-echo sequence technique, 
in the axial plane (20). Standard small field-of-view (FOV) 
axial, sagittal and coronal T2-weighted fast spin-echo (FSE) 
images were also acquired for comparison, as per routine 
MRI protocol. The T2-mapping and T2-weighted FSE 
scan parameters are summarized in Table 1. In addition, the 
color-coded parametric T2-maps for each scan were derived 
using evaluation software.
1813Quantitative Imaging in Medicine and Surgery, Vol 10, No 9 September 2020
© Quantitative Imaging in Medicine and Surgery. All rights reserved.   Quant Imaging Med Surg 2020;10(9):1811-1822 | http://dx.doi.org/10.21037/qims-20-222
The other MRI sequences acquired were: axial DWI (with 
acquired b values of 0, 50, 500, 1,000 s/mm2, and calculated b 
value: 1,400 s/mm2), large FOV axial T1-weighted spin-echo 
sequence of the whole pelvis and DCE imaging. The DWI 
and DCE imaging sequences were used for assessing prostate 
changes according to PI-RADS version 2, with the aim of 
generating the reference standard for each case, while the 
T1-weighted sequence was used to assess for hemorrhage. 
The DWI, DCE and T1-weighted images otherwise were 
not subjected to investigation in this study.
Image analysis
The prostate was divided into the PZ and the TZ, based on 
the standard T2-weighted FSE sequence. The central zone 
was considered part of the TZ in this study.
Three readers of varying experience in prostate MRI, 
R1 (a final year radiology resident), R2 (a junior radiology 
consultant with 5 years of experience with prostate MRI) 
and R3 (a senior radiology consultant with 15 years of 
experience with prostate MRI) separately reviewed two 
sets of images for each patient: (I) axial T2-weighted 
FSE sequence (standard T2) and (II) T2-mapping with 
reconstructed color-coded parametric T2-map. Since T2-
mapping was derived from axial T2-weighted images, 
the readers were only required to review the standard T2 
images in the axial plane. To allow a uniform standardized 
comparison, the sagittal and coronal T2-weighted, DWI, 
DCE and T1-weighted images were not made available 
to readers for review. The readers were also blinded to 
histological findings. The reading was conducted in two 
sessions 1 week apart, to avoid recall bias.
The first reading session involved reviewing the standard 
T2 images. First, a T2 PI-RADS score of 1 to 5 was 
assigned to the most suspicious lesion in each prostatic 
zone based on PI-RADS version 2 guidelines (21). If there 
was no focal lesion, a T2 PI-RADS score of 1 was assigned 
(normal). This score was modified to reflect the probability 
of clinically significant prostate malignancy on a Likert-like 
scale (Table 2).
In the second reading session, the standard T2 and the 
parametric T2-maps were reviewed in combination and 
the most suspicious lesion in each prostatic zone was again 
assigned a probability score for clinically significant cancer 
based on a Likert-like scale (Table 2). This was performed 
qualitatively by evaluating the morphology on the standard 
T2, and quantitatively using the parametric T2-maps by 
applying a threshold T2-relaxation time of 99 ms below 
which the suspicion of malignancy is increased (19). During 
quantitative assessment using the parametric T2-maps, a 
region of interest (ROI) in each zone was marked with a 
circular marker and the mean T2-relaxation time within 
the ROI was recorded. The T1-weighted sequence was 
also evaluated to avoid areas of hemorrhage or calcification 
while marking the ROI.
Reference standard
As not all patients had histological correlation available, the 
PI-RADS score in each zone was taken as reference standard, 
Table 1 T2-weighted imaging and T2-mapping scan parameters
Scan parameter T2-weighted FSE T2-mapping
TR (ms) 4,040 4,820
TE (ms) 116 Measured: 10.8–172.8 (10.8 ms intervals); simulated: 50, 100, 116, 130, 150
Turbo factor 25 –
Flip angle (degrees) 160 180
In-plane resolution (mm) 0.52×0.47 0.75×0.56
Slice thickness (mm) 3 (no gap) 3 (no gap)
FOV (mm) 180 180
Acceleration factor (GRAPPA) 2 2
Bandwidth (Hz/pixel) 200 220
Scan time 3 min 56 s 3 min 58 s
FSE, fast spin-echo; TR, repetition time; TE, echo time; FOV, field-of-view.
1814 Lee et al. T2-mapping prostate cancer
© Quantitative Imaging in Medicine and Surgery. All rights reserved.   Quant Imaging Med Surg 2020;10(9):1811-1822 | http://dx.doi.org/10.21037/qims-20-222
taking into account DWI and DCE imaging as well (“overall 
PI-RADS score”). This score was assigned in consensus by 
two expert observers (with combined 25 years of prostate 
MRI experience) not involved in the readings. The full MRI 
study (including axial, coronal and sagittal T2-weighted, 
DWI and DCE imaging) were available for review by the 
two expert observers. In our study, an overall PI-RADS score 
of 1–3 was considered reference standard negative while an 
overall PI-RADS score of 4 and 5 was considered reference 
standard positive for malignancy (22,23).
Statistical analysis
Inter-observer agreement between three readers for 
standard T2 and combined standard T2 with T2-mapping 
was calculated using the intraclass correlation coefficient 
(ICC) for more than two observers.
The T2 PI-RADS scores for standard T2 and the Likert 
scores for combined standard T2 with T2-mapping were 
compared using the area under the receiver operating 
characteristic curve (AUROC).
Point estimates for Sn, Sp, positive predictive values 
(PPVs) and negative predictive values (NPVs) were derived 
by constructing the 2×2 contingency table. Diagnostic 
performance in terms of Sn, Sp, PPV and NPV for standard 
T2 alone and combined standard T2 with T2-mapping were 
compared using the McNemar Test for paired observations.
In a subgroup analysis, for each zone assigned a particular 
T2 PI-RADS score, the diagnostic accuracy of standard T2 
alone and combined standard T2 with T2-mapping was 
compared using the McNemar Chi-Square test.
For purposes of statistical analysis, a reader-assigned T2 
PI-RADS or Likert scale score of 1 to 3 was considered as 
scan-negative while a score of 4 to 5 was considered scan-
positive for malignancy.
Individual reader and overall results are presented with 
95% confidence intervals (CIs) and P values. Significance 
level for all comparisons was set at 5%. Statistical analysis 
was performed using SPSS Statistics for Windows, version 
21.0 (IBM Corp., Armonk, NY, USA).
Results
The probability scores assigned by each reader as well as 
the overall PI-RADS scores (reference standard) assigned in 
consensus by two expert observers, with their distribution 
across the PZs and TZs, are summarized in Table 3.
There was fair agreement between all three readers for 
standard T2 (ICC =0.56) and combined standard T2 with 
T2-mapping (ICC =0.58).
The overall AUROC (Figure 1) was also higher for 
combined standard T2 with T2-mapping, but this was not 
statistically significant (0.89 vs. 0.82, P=0.31).
The combined Sn for all readers was significantly higher 
for combined standard T2 with T2-mapping compared 
to standard T2 alone (73.0% vs. 49.2%, P=0.006) in the 
detection of prostate cancer. The combined NPV was 
also higher for combined standard T2 with T2-mapping, 
approaching statistical significance (90.3% vs. 84.9%, 
P=0.07). However combined Sp was borderline significantly 
lower for combined standard T2 with T2-mapping 
compared to standard T2 alone (89.3% vs. 94.9%, P=0.05). 
There was no significant difference between the combined 
PPV (P=0.45). These results are summarized in Table 4.
In a subgroup analysis, the T2 PI-RADS score assigned 
on standard T2 in the first reading session was compared 
to the corresponding Likert score assigned for combined 
standard T2 with T2-mapping in the second reading 
session, for each zone. This was performed to assess if there 
was a subgroup where the addition of T2-mapping to T2-
weighted imaging would be particularly useful. This analysis 
showed that the addition of T2-mapping significantly 
Table 2 Scoring scale for probability of prostate malignancy in each zone
T2 PI-RADS score (for 
standard T2)
Likert-like score (for simulated T2 and combined standard T2 
with T2-mapping)
Probability of clinically significant prostate 
malignancy




5 5 Very high
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increased the diagnostic accuracy compared to standard T2 
alone, for zones assigned a T2 PI-RADS score of 3 (79.7% 
for combined standard T2 with T2-mapping vs. 63.8% 
for standard T2 alone, P=0.04). For zones assigned T2 PI-
RADS scores of 2, 4 or 5, the addition of T2-mapping did 
not significantly improve diagnostic accuracy. These results 
are summarized in Table 5.
TZs assigned with a T2 PI-RADS score of 3 were 
further reviewed. Across all three readers, there were 
31 zones assigned a T2 PI-RADS score of 3. The addition 
of T2-mapping correctly “downgraded” the probability 
scores in 13 zones to a “low probability of clinically 
significant prostate cancer” (Likert-like score 2) whilst 
correctly “upgraded” the probability scores in two zones 
to a “high or very high probability of clinically significant 
Table 3 Probability scores (based on Table 2) assigned by each reader and the overall PI-RADS score assigned in consensus by two expert 
observers (as reference standard), with their distribution in the PZ and TZ
Reader
Probability scores for clinically significant 
prostate cancer 
PZ TZ
2 3 4 5 2 3 4 5
Reader 1 Standard T2 14 10 10 6 23 8 3 6
Standard T2 + T2 map 13 8 13 6 22 7 6 5
Reader 2 Standard T2 12 11 16 1 26 11 1 2
Standard T2 + T2 map 14 7 9 10 31 8 0 1
Reader 3 Standard T2 14 15 6 5 24 13 0 3
Standard T2 + T2 map 22 6 7 5 32 5 1 2
Reference standard – 23 2 8 7 33 1 0 6














Standard T2 + T2-mapping
Standard T2 alone
Figure 1 Overall receiver operating characteristic curves for 
combined T2-weighted imaging with T2-map and T2-weighted 
imaging alone.
Table 4 Comparison of the combined diagnostic performance for T2-weighted imaging alone and in combination with T2-mapping
Statistical parameter Standard T2 alone Combined standard T2 with T2-mapping P value
AUROC (95% CI) 0.82 (0.73, 0.91) 0.88 (0.81, 0.95) 0.31
Sn (95% CI), % 49.2 (36.4, 62.1) 73.0 (60.4, 83.4) 0.006*
Sp (95% CI), % 94.9 (90.6, 97.7) 89.3 (83.8, 93.4) 0.05^
PPV (95% CI), % 77.5 (63.5, 87.2) 70.8 (60.7, 79.2) 0.45
NPV (95% CI), % 84.0 (80.4, 87.0) 90.3 (86.1, 93.3) 0.07
*, combined Sn significantly higher for combined T2-weighted imaging and T2-mapping; ^, combined Sp borderline significantly lower for 
combined T2-weighted imaging and T2-mapping. CI, confidence interval; AUROC, area under the receiver operating characteristic curve; 
Sn, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value.
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Figure 2 Prostate mpMRI of a 51-year-old gentleman with a PSA of 6.9 ng/mL. (A) T2-weighted imaging showed a focal hypointense 
lesion in the PZ of the right prostatic lobe (arrow); (B) ADC map also showed focal hypointensity (arrow); (C) there was corresponding 
mild hyperintensity on high b value DWI (b=1,400) (arrow); (D) DCE-imaging showed focal early enhancement on DCE-imaging in the 
PZ in the right midgland (arrow). This was given an overall PI-RADS 4 by expert consensus (reference standard positive for malignancy); 
(E) T2-mapping showed T2-relaxation time of 85.1 ms in the PZ at the right midgland, below threshold value of 99 ms (arrow). All three 
readers assigned a T2 PI-RADS score of 3 but correctly upgraded to a Likert score of 4 based on combined T2 and T2-mapping. mpMRI, 
multiparametric magnetic resonance imaging; PSA, prostate-specific antigen; PZ, peripheral zone; ADC, apparent diffusion coefficient; 




prostate cancer” (Likert-like score 4 or 5). There was no 
incorrect downgrading or upgrading of scores for this subset 
of zones although in the remaining 16 zones, addition of 
T2-mapping did not change the probability scores.
Case examples are shown (Figures 2-4).
Discussion
Prostate cancer detection using mpMRI, even with 
standardization of imaging technique, interpretation and 
reporting, remains subjective and dependent on reader 
experience (24,25). Quantitative imaging techniques are able 
Table 5 Subgroup analysis by T2 PI-RADS score
T2 PI-RADS score
Overall accuracy standard T2 alone 
(95% CI), %
Overall accuracy combined standard T2 with T2-mapping 
(95% CI), %
P value
1 – – –
2 92.4 (86.4, 96.3) 90.8 (84.6, 95.2) 0.66
3 63.8 (51.3, 75.0) 79.7 (68.3, 88.4) 0.04*
4 69.6 (47.1, 86.8) 69.6 (47.1, 86.8) 1
5 82.4 (56.6, 96.2) 76.5 (50.1, 93.2) 0.67
Subgroup analysis by T2 PI-RADS score, showing that combined T2-weighted imaging and T2-mapping significantly increased accuracy 
compared to T2-weighted imaging alone, for zones assigned a T2-PI-RADS score 3 (*). CI, confidence interval.
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Figure 3 Prostate mpMRI of a 60-year-old gentleman with a PSA of 5.1 ng/mL. (A) T2-weighted imaging showed a focal wedge-shaped 
hypointensity in the PZ at the left apex (arrow); (B) ADC map showed corresponding mild focal hypointensity (arrow); (C) this was iso-
intense on high b value DWI (b=1,400) (arrow); (D) DCE-imaging showed no early enhancement (arrow). The overall PI-RADS score was 
2 (reference standard negative for malignancy); (E) T2-mapping showed a T2-relaxation time of 118.7 ms, above threshold value of 99 ms 
(arrow). This was assigned a T2 PI-RADS score of 4 by reader R2. However, this was correctly re-categorized to a Likert score of 2 based 
on combined T2 and T2-mapping. mpMRI, multiparametric magnetic resonance imaging; PSA, prostate-specific antigen; PZ, peripheral 




to provide measurements for increased objectivity in image 
analysis and are increasingly being studied in the evaluation 
of prostate cancer (26). There is substantial literature 
demonstrating the usefulness of T2-relaxation times derived 
from quantitative T2-mapping in the detection of prostate 
malignancy (17,18,27,28).
In our study, we attempted to assign a single threshold 
T2-relaxation time in the quantitative assessment of the 
parametric T2-maps. However, this was challenging due to 
considerable overlap of T2-relaxation times between benign 
stromal hyperplasia and TZ malignancy (29,30). While one 
study proposed a cut-off T2-value of 99 ms for identifying 
malignancy in the PZ (19), no such cut-off could be 
recommended for TZ malignancy. Therefore, in our study, 
in addition to applying this recommended threshold T2-
relaxation time while analyzing the parametric T2-maps, 
we also included evaluation of morphology on T2-weighted 
imaging, and not just assigning a probability score based 
on T2-relaxation times alone. We believe this should also 
reflect the way T2-mapping is utilized in clinical practice, 
and underscores the importance of assessing lesion shape 
and margins on T2-weighted imaging, particularly in the 
TZ (31).
Our study involved multiple readers in a zone-by-zone 
analysis of the prostate. This was suggested to be more 
relevant to clinical practice as compared to a region-of-
interest analysis (22). Also, our patient cohort consisted of 
subjects without known prostate malignancy at the time of 
scan, a few of whom eventually had biopsy-proven prostate 
malignancy. This approach was chosen to be more reflective 
of the imaging spectrum in clinical practice given that 
mpMRI of the prostate is increasingly the first investigation 
of choice in the initial evaluation of a raised PSA level (32,33).
Our results appear to be mixed when compared to 
available literature. In our study, combined standard T2 
with T2-mapping provided higher Sn and NPV compared 
to standard T2 alone for detection of prostate malignancy. 
However, there was trade-off with reduction in Sp. We 
noted that there is little comparable evidence in the 
literature and no optimal method on the utilization of 
1818 Lee et al. T2-mapping prostate cancer




Figure 4 Prostate mpMRI of a 69-year-old gentleman with PSA of 9.3 ng/mL. (A) T2-weighted imaging showed a hypointense lesion with 
partially-obscured borders in the TZ in the right prostatic lobe (arrow); (B) ADC map showed marked hypointensity (arrow); (C) high b 
value DWI (b=1,400) showed corresponding marked hyperintensity (arrow). This was given an overall PI-RADS 5 (reference standard 
positive for malignancy). Also, in this case, targeted biopsy performed after MRI showed Gleason 5+5 prostate cancer; (D) T2-mapping 
showed a T2-relaxation time of 80.7 ms, below threshold value of 99 ms (arrow). Readers R1 and R2 assigned a T2 PI-RADS score of 3 
and both appropriately upgraded to a Likert score of 5 based on combined T2 and T2-mapping. No intravenous contrast was administered 
in this patient. mpMRI, multiparametric magnetic resonance imaging; PSA, prostate-specific antigen; TZ, transition zone; ADC, apparent 
diffusion coefficient; DWI, diffusion-weighted imaging.
T2-mapping with standard mpMRI sequences. Wu et al. 
compared diagnostic performance of T2-weighted imaging 
and T2-star-mapping and found that the combination 
of T2-weighted imaging and T2-star-mapping provided 
a significantly higher AUROC, Sn, Sp and accuracy 
compared to T2-weighted imaging alone (22). However, 
the method of utilizing the T2-star-maps in that study was 
not clear. Chatterjee et al. found no significant differences 
in the sensitivities and specificities between T2-weighted 
imaging and T2-mapping although a significantly higher 
PPV for T2-mapping was noted (23). However, it was not 
clear in that study, if the T2-maps were utilized alone or in 
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conjunction with T2-weighted imaging. Most importantly, 
the patient cohort in these two studies was biased in favor 
of prostate malignancy as all patients had histologically-
proven prostate malignancy and had undergone radical 
prostatectomy. One possible explanation for the reduction 
in Sp for combined standard T2 and T2-mapping in our 
study could be due to the fact that DWI and DCE imaging, 
which have been shown to increase Sp compared to 
T2-weighted imaging alone, were not made available to 
the readers (34). Although this might limit the applicability 
in actual clinical practice, this approach was adopted to 
allow uniform comparison between standard T2 and 
T2-mapping, and also because it has not been established 
how T2-mapping complements mpMRI in clinical practice.
In our study, T2-mapping was most accurate when 
used to re-assess lesions that were deemed of intermediate 
probability of malignancy on standard T2 (T2 PI-RADS 
score 3). For lesions that were already classified on standard 
T2 as low probability of malignancy (T2 PI-RADS score 1 
or 2) or high probability of malignancy (T2 PI-RADS score 
4 or 5), the addition of T2-mapping was not helpful. Given 
that the PI-RADS version 2 grading of TZ lesions relies 
heavily on T2-weighted imaging, T2-mapping could be 
useful in distinguishing malignancy for PI-RADS 3 lesions 
in the TZ, and this appears to be supported by our review 
of the TZs in our study which were assigned a T2 PI-RADS 
score of 3. However, in our patient cohort there were too 
few zones in the TZ assigned an overall PI-RADS score of 
4 or 5 (6/40 zones), therefore we were not able to perform 
a meaningful statistical analysis. This reflects the fact that 
the majority of prostate malignancies occur in the PZ (35). 
The difficulty in evaluating the usefulness of T2-mapping 
for TZ malignancies due to the relatively low incidence was 
also highlighted in other studies (28,36,37).
We observed substantial interobserver variability in 
analyzing the combined standard T2 with T2-mapping, as 
evidenced by only “fair” agreement between readers. This 
suggests that while quantitative measurements should help 
increase objectivity in imaging analysis, different readers 
may utilize the parametric T2-maps in combination with 
T2-weighted imaging differently, with some preferring to 
place greater emphasis on the T2 and some preferring to 
place greater emphasis on measured tissue T2-relaxation 
times from T2-mapping.
Our study has several limitations. First, not all the 
subjects in our patient cohort eventually had biopsy or 
proven prostate malignancy. In the study cohort, only 14 
out of 40 subjects underwent prostate biopsy. Therefore, we 
adopted a cumulative reference standard of expert-assigned 
overall PI-RADS score (taking into account DWI and DCE 
imaging). Reference standard of biopsy or prostatectomy 
would usually be ideal for correlation of MRI findings. We 
agree our results might not have been truly validated in our 
study in terms of histological correlation. Also because of 
this, we were unable to make a head-to-head comparison 
between T2-mapping, DWI and DCE imaging, which 
would have been ideal. However, biopsy and MRI findings 
might not always correlate due to either inconsistencies 
in sample labelling, sampling error or inherent limitations 
of MRI (38). This can be difficult to determine without 
analysis of whole-mount prostatectomy specimen. 
Moreover, in our patient cohort where the majority does not 
have a prostate malignancy, correlating with histology from 
prostatectomy would not be practical. Furthermore, our 
study aimed to evaluate the clinical utility of T2-mapping 
and how it could potentially be used to complement existing 
mpMRI sequences, rather than diagnostic accuracy of T2-
mapping for cancer detection.
Secondly, whilst our study shows that T2-mapping 
could be helpful in evaluation of T2 PI-RADS 3 lesions, in 
current practice this would be relevant only if DWI and/or 
DCE imaging is non-diagnostic (31). Therefore, excluding 
reader assessment of DWI and DCE imaging in our study is 
somewhat artificial and may limit applicability of our study 
in the clinical setting.
Thirdly, one problem with adopting expert-assigned 
overall PI-RADS score as reference standard would be the 
dilemma of PI-RADS 3 scores. Whilst overall PI-RADS 
scores of 1–2 and 4–5 were reasonably classified as reference 
standard negative and positive for malignancy, PI-RADS 
score of 3 was less clear. Given the variable rate of clinically 
significant malignancy in PI-RADS 3 lesions, ranging from 
5–26% (39-41), we therefore classified overall PI-RADS 
score 3 as reference standard negative for malignancy for 
purposes of statistical analysis. Similarly, we considered a 
reader-assigned T2 PI-RADS score of 3 as scan-negative 
for malignancy, given the relatively low Sn of T2-weighted 
imaging for prostate cancer detection (42,43). This method 
of stratification was also performed by Wu et al. and 
Chatterjee et al. (22,23).
Finally, the exact lesion locations in our study were not 
assessed. The location of the reader-identified lesion might 
not represent that of the reference standard, apart from 
whether it was located in the PZ or TZ. However, this was 
to avoid inter-reader ambiguity in definition of the prostatic 
apex, midgland and base, particularly for small-volume 
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prostates. Midline lesions might also cause confusion 
between readers with regards to the laterality (i.e., left or 
right prostatic lobe). Moreover, there were many subjects 
with only BPH nodules and identifying a particular nodule 
in a specific location is usually not clinically relevant in such 
cases.
In conclusion, quantitative T2-mapping shows potential 
for improved detection of clinically-significant prostate 
malignancy, when read in conjunction with T2-weighted 
imaging. By applying a threshold tissue T2-relaxation time 
of 99 ms, a combination of T2-weighted imaging and T2-
mapping increases Sn and NPV for prostate malignancy 
compared to T2-weighted imaging alone. T2-mapping was 
particularly useful in re-categorizing T2 PI-RADS 3 lesions 
(of intermediate probability of cancer) into either low or 
high probability of malignancy. However, the application of 
T2-mapping in conjunction with DWI and DCE imaging as 
part of mpMRI of the prostate remains uncertain. Further 
studies are recommended to determine the optimal method 
of utilizing T2-mapping in clinical practice, and to define 
its role in complementing established mpMRI sequences.
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